Apr 7, 2026
Today’s guest is Emma Vitalini, Head of Global Digital Health
Technology Innovation at Amgen. Amgen is a global biotechnology
company focused on discovering, developing, and delivering
medicines for serious illnesses. Emma joins Emerj Editorial
Director Matthew DeMello to examine how data and AI are reshaping
patient recruitment, decentralized clinical trials, and compliance
workflows in highly regulated healthcare environments.
Emma also discusses practical ways AI can surface unstructured
genomic and clinical data to improve patient identification, how
API-based access supports hypothesis testing without large-scale
data movement, and how modular consent and explainable AI
frameworks help sponsors scale trial operations while maintaining
regulatory trust and patient transparency.
Learn how brands work with Emerj and other Emerj Media options
at go.emerj.com/partner